CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 60 enrolled
Drug / intervention
placebo +2 moredrug
Likely dose
Galantamine 8mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01880099
NCT01880099N/ACompleted
CompareCT.gov

Cholinergic Enhancement as a Treatment for Nicotine Addiction

Yale University·interventional·Posted Jun 18, 2013·Updated Mar 23, 2020

In Brief

A clinical study evaluating placebo, Galantamine 8mg, and 1 other intervention for Nicotine Dependence. Completed, enrolled 60 participants across 1 site.

Detailed Summary

You are invited to participate in a research study at the VA Connecticut Healthcare System (West Haven campus) that examines whether a medication called galantamine can improve your learning and memory, and also help you to quit smoking. You have been invited to participate because you currently smoke cigarettes, and want to quit smoking. If you are eligible and agree to be in the study, your participation will last for approximately 8 weeks. To determine if galantamine (8 or 16 mg) is superior to placebo a) in reducing smoking self-administration in a human laboratory model and b) improving abstinence rates at the end of 4 weeks of treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNicotine Dependence
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 18, 2013
Enrollment StartDec 1, 2013
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 13.0 years ago

Interventions

placebodrug

placebo compared to 8mg of Galantamine

Galantamine 8mgdrug

8mg of galantamine compared to placebo

Galantamine 16mgdrug

16mg of galantamine compared to placebo